Lithium is the gold-standard treatment for bipolar disorder, a severe mental illness. A large body of evidence suggests that inflammation plays a role in the pathogenesis of bipolar disorder and that mood stabilizers exhibit anti-inflammatory properties. However, contradicting findings have also been reported. In this study, we examined the effects of lithium on LPS-induced inflammation in rat primary glia cells. Cells were pre-treated with lithium (1 or 10 mM) for 6 or 24 h, after which, inflammation was induced by the addition of LPS (for another 18 h) to the culture medium. Thereafter, medium was collected and cells were harvested for further analyses. Levels of TNF-a, IL1-b and PGE 2 were determined by ELISA and NO levels by the Griess reaction assay. Expression levels of cyclooxygenase-2 (COX-2) and inducible NO synthase (iNOS) were examined by Western blot analysis. We found that pre-treatment with lithium 10 mM (but not 1 mM) significantly reduced LPS-induced secretion of TNF-a, IL1-b, PGE 2 and NO. In addition, lithium significantly reduced the expression of COX-2 and iNOS. These findings indicate that lithium exhibits a potent anti-inflammatory effect. However, it's important to emphasize that this effect was obtained mainly under treatment with an extra-therapeutic concentration of the drug.
Introduction
Lithium is the classic pharmacotherapy for bipolar affective disorder. 1, 2 Bipolar disorder (manic-depressive illness) is a severe and chronic mental illness, affecting approximately 1%-1.5% of the general population. 1, 3 It is characterized by alternating shifts of mania and depression, both of which severely affect the mental, physical, social and functional status of affected patients. 1, 4, 5 Lithium is the most useful mood stabilizer for maintenance treatment of bipolar disorder. 1, 2, 6, 7 The use of lithium is expected to further increase in coming years as it has recently been suggested as a treatment for other illnesses, including schizoaffective disorder, 8 neurodegenerative diseases, such as Alzheimer's disease [9] [10] [11] and amyotrophic lateral sclerosis. 12 Nevertheless, lithium therapy is complicated by two significant factors: firstly, it has a narrow therapeutic index, necessitating close monitoring of drug plasma concentration; and, secondly, it has several side effects, some of which are severe and occasionally irreversible. 1, [13] [14] [15] The mechanism of action of lithium in the treatment of bipolar disorder is not fully understood. Several hypotheses have been suggested to explain its therapeutic mechanisms; [16] [17] [18] however, a conclusive mechanism is still lacking.
Accumulating evidence suggests that lithium, and other mood stabilizers, exhibit anti-inflammatory properties [19] [20] [21] and that inflammation contributes to the pathological processes underlying bipolar disorder. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Moreover, inflammation has been extensively linked to the pathophysiology of depression. 23, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Other neurological disorders, including schizophrenia, [42] [43] [44] Alzheimer's disease, 22, 45, 46 Parkinson's disease 47 and epilepsy 48 have also been associated with inflammation. The mechanism of the inflammatory responses involved in these illnesses is poorly understood. It is suggested that pro-inflammatory mediators, including prostaglandins (PGs), cytokines (e.g. IL1-b and TNF-a) and C-reactive protein play an important role. For example, bipolar patients had increased levels of pro-inflammatory mediators such as IL-6, 20, 28, 29 TNF-a 20, 28, 29 and C-reactive protein. 20, 24, 25, 28 In addition, monocytes of bipolar patients were found to have a gene expression signature characterized by overexpression of multiple inflammatory genes. 27 Bipolar disorder has also been associated with altered regulation and synthesis of PGs. 19, 21, 26, 27 The results regarding anti-inflammatory cytokines, such as IL-4 and IL-10 have been less consistent. 20, 29 The connection between mood disorders and inflammation is further strengthened by a large body of evidence suggesting that patients with depression have increased levels of pro-inflammatory mediators, 22, [30] [31] [32] [33] 35, 36, 41 while levels of anti-inflammatory cytokines are unchanged, 20, 22, 23 or either reduced. 41 Similarly, depression is characterized by alterations in the production and regulation of PGs. 19, 21, 36 Taken together, these, and other observations, laid the foundation for the rapidly developing 'inflammation hypothesis' of mood disorders. 20, 21, 31, 33, 49 One of the cellular pathways that has been extensively linked with brain inflammation and the pathophysiology of mood disorders is that of the enzyme cyclooxygenase (COX), 19, 21 which produces PGs. PGs (such as PGE 2 ) are pivotal mediators of tissue homeostasis and their aberrant regulation is known to cause deleterious pathophysiological effects. 50, 51 The biosynthesis of PGs involves phospholipase A 2 -mediated release of arachidonic acid (AA) from membrane phospholipids and its conversion to PGs by COX. 50, 51 There are three COX enzymes, referred to as COX-1, COX-2 and COX-3. COX-1 produces PGs that are important for homeostasis and physiological functions and is expressed constitutively in most tissues. 52 COX-2 is an inducible enzyme, whose induction is believed to be a response to inflammatory or mitogenic stimuli. 52 Nevertheless, it's known that COX-1 and COX-2 have some over-lapping functions and that, in certain conditions, COX-1 can be up-regulated and contribute to inflammatory responses, 53, 54 while COX-2 is constitutively expressed in some tissues (e.g. endothelium, brain and kidney) where it accounts for important physiological functions. 53, 55 The regulation and function of COX-3 are still unknown.
Another pathway that is associated with brain inflammation is that of NO. [56] [57] [58] In the brain, NO is synthesized constitutively in post-synaptic neurons by the enzyme neuronal NO synthase (nNOS). 57 Alternatively, after inflammatory stimuli, NO is produced in glia cells by the enzyme inducible NOS (iNOS). 56 NO is a very active signalling molecule of the brain, associated with multiple cellular processes and signal transduction pathways. 58 Although it has been suggested that NO plays a role in the pathophysiology and treatment of bipolar disorder, 59, 60 the results show an inconsistent pattern.
In line with the 'inflammation hypothesis' of mood disorders, mood-stabilizing drugs were found to exhibit potent anti-inflammatory properties. [19] [20] [21] Rapoport et al. have shown that mood stabilizers decrease brain concentration of PGE 2 and attenuate the turnover of AA. 19, 21 For example, chronic lithium administration decreased AA turnover, COX-2 activity and PGE 2 concentration in the rat brain. 61 Similarly, chronic treatment with valproate 62 and Carbamazepine 63 reduced AA turnover, COX-2 activity and PGE 2 levels in rat brain, and chronic Lamotrigine administration decreased COX-2 expression in rat frontal cortex. 64 Consistent with a role for AA metabolites in the pathogenesis of bipolar disorder and the therapeutic mechanisms of mood-stabilizing drugs, treatment with celecoxib, a selective COX-2 inhibitor was found to be beneficial in a double-blind, placebo-controlled trial of bipolar patients. 49 Similarly, in double-blind trials of patients with major depression 33 and schizophrenia, 42, 43 treatment with selective COX-2 inhibitors led to favourable effects. Furthermore, it was shown that chronic treatment with celecoxib alleviated depressive-like symptoms in rats and reversed the elevation in COX-2 expression and PGE 2 levels in the brain. 65 It has also been suggested that antipsychotic 43 and antidepressant drugs 66, 67 confer anti-inflammatory properties. Alternatively, other studies, mostly conducted in non-brain cells, have given inconsistent results with regard to the effect of mood stabilizers on components of the inflammatory response. For example, in contrast to previous reports 61,62 that found lithium and valproate to decrease COX-2 protein levels in rat brain, lithium was found to enhance expression of COX-2 in renal and mammary cells. 68, 69 Another study showed that the effect of lithium on COX-2 expression is tissuespecific, as it reduced expression in kidney inner medulla but increased expression in the renal cortex. 70 Thus, although many reports demonstrated that lithium attenuates the inflammatory response, contradictory findings have also been reported.
The present study was undertaken to test the effects of lithium on LPS-induced inflammation in rat primary glia cells. Glia cells (microglia, astrocytes and oligodendrocytes) play a pivotal role in immune and inflammatory processes of the brain. 71, 73 Microglia are the CNS equivalent of macrophages. They inspect the brain for tissue damage and infection and help in maintaining brain homeostasis by removing toxic debris and dead cells. In response to an inflammatory stimulus such as LPS, microglia release multiple inflammatory mediators (such as NO, TNF-a and PGE 2 ). [71] [72] [73] [74] Astrocytes are supportive to neurons and allow them to function properly. 71, 72 Moreover, by producing growth factors and removing toxic cell debris, astrocytes enhance the viability and survival of neurons. Similarly to microglia, the induction of astrocytes by inflammatory stimuli induces morphological changes, followed by secretion of inflammatory mediators. Oligodendrocytes are pivotal for normal electrical communication between neurons. 72 They produce myelin which covers axons and facilitate the conduction of electrical impulses. 72 Therefore, primary glia cells are a model system that is highly relevant to the study of neurological disorders, including manic-depressive illness.
Materials and methods

Primary rat glia culture
Primary cultures of mixed glia cells were extracted from Wistar newborn (0-24 h) rat brains. The procedures were used in accordance with the Guidelines of the Faculty of Health Sciences Committee on the Use and Care of Laboratory Animals (Authorization # IL-04-01-2009). Glia cells extraction was performed as previously described. 75 Briefly, brains were removed under sterile conditions and washed four times with sterile 0.9% NaCl solution. Then, meninges and blood vessels were removed and the brains were minced, passed through a steel mesh (with 280 mm diameter clefts) and then through nylon sieves (120 mm pore size) to obtain single cells. The dissociated cells were pelleted twice by centrifugation at a low speed (1200 g) and washed with saline. The final cell suspension was in a high glucose (4.5%) DMEM containing 10% inactivated FCS, antibiotics (penicillin 100 unit/ml and streptomycin 100 mg/ ml), 2 mM L-glutamine and 0.2 unit/ml insulin (regular). After cell count with a coulter, 10 6 cells/ml were seeded in 24-well plates that were coated with 0.01 mg/ml poly-L-lysine. The plates were incubated at 37 C in an atmosphere of 5% CO 2 in air. The medium was replaced after 1-3 d and once a wk thereafter. After 2-3 wk, when the cultures were almost free of neurons and contained mainly glia cells, experiments were conducted. For instance, at this stage, cultures contain >95% glia cells ($80% astrocytes, $15% microglia) and less than 5% neurons, as described previously. 75 
Experimental procedure
Escherichia coli LPS (Sigma) was used to induce inflammation in glia cultures. Lithium was used at the following concentrations: 1 mM and 10 mM. We examined the effects of lithium on LPS-induced secretion of inflammatory mediators (including TNF-a, IL-1b, PGE 2 and NO) to the culture medium. Moreover, we determined the effect of lithium on expression level of COX-2 and iNOS-enzymes that are induced during inflammatory processes in the brain. Cells were treated with lithium for 6 h or 24 h before the addition of LPS to the culture medium, after which, LPS was added for another 18 h. Subsequently, samples were collected and stored at À20 C for further determination.
Determination of TNF-, IL-1 and PGE 2 levels
Samples were assayed for TNF-a, IL-1b and PGE 2 protein content using ELISA kits, according to the manufacturer's protocols (R&D Systems). The optical density of standard and unknown samples was determined by using a spectrophotometer set to 450 nm. The detection limit of TNF-a and IL-1b assays was 62.5 pg/ml. The detection limit of the PGE 2 assay was 39 pg/ml. In the samples where the level of the examined inflammatory mediator was below the detection limit, results were expressed as 'undetectable'.
Determination of NO levels
Levels of NO in culture medium were determined by measuring the concentrations of nitrite (NO 2 À ), a stable metabolite of NO, using the Griess reaction assay. 76 One hundred ml of samples and standard solution of known concentrations of NaNO 2 (0.39-12.5 mM) were transferred into a 96-well plate. These were mixed with an equal volume of Griess reagent (Sigma, St Louis, MO, USA), which contains 1% sulfanilamide and 0.1% N-1-naphthylethylendiamine dihydrochloride. The plate was incubated in the dark at 20-24 C for 15 min. The absorbance of the reaction products was measured at 540 nm using a spectrophotometer.
Western blot analysis
Glia cells were grown in small, poly-L-lysine-coated flasks, with 6x10 6 cells seeded on each flask. Cells were harvested and lysed in 200 ml ice-cold lysis buffer [50 mM Tris HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, Triton X-100 (0.1% w/v), 50 mM NaF, 1 mM sodium vanadate, 1 mM PMSF, 1 mM leupeptin, 20 u/ml aprotinin]. Lysates were transferred to Eppendorf tubes and incubated for 8 min on ice. Extracts were then centrifuged at 12,000 g, for 15 min at 4 C. Protein concentration in samples (supernatants) was determined by the method of Bradford. 77 Aliquots of samples, reconstituted with appropriate amounts of Laemmli's loading buffer and boiled for 5 min, were resolved (40 mg protein/well) on 10% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (BioRad, Hercules, CA). Membranes were briefly exposed to Ponceau buffer to verify the transfer of protein to the membranes. Membranes were incubated 18-20 h (at 4 C) with primary antibodies against COX-2 and iNOS (Cayman, Ann Arbor, MI), followed by incubation for 1 h with a HRP-conjugated secondary Ab (Jackson Immuno-Research Laboratories, Baltimore, PA). Actin was used as an internal control to normalize for loading variations and was detected using an anti-actin Ab (MP Biomedicals, Solon, OH). Immunocomplexes were visualized by enhanced chemiluminescence, using exposure to Fuji medical x-ray film for 5 sec. Bands were quantified by densitometric scanning using a 202D Bio Imaging System (Pharmacia, Bridgewater, NJ) with a Fuji-Film Thermal Imaging System FTI-500 (Fuji, Tokyo, Japan) and TINA software (Raytest, Straubenhardt, Germany). after LPS 100 ng/ml exposure. Moreover, PGE 2 secretion ( Figure 2C ) gradually increased reaching its peak at 30 h of LPS exposure. Based on these results, we decided to examine the effects of lithium on secretion of inflammatory mediators at 18 h post LPS induction. This is because at 18 h post-LPS induction, the levels of all the examined inflammatory mediators were prominently elevated.
Presentation of the data and statistical analysis
Effects of lithium on LPS-induced secretion of NO, TNF-, IL-1 and PGE 2
To test the effect of lithium on LPS (100 ng/ml)-induced secretion of NO, TNF-a and IL-1b, cells were treated with lithium for 6 h or 24 h before the addition of LPS to the culture medium. The rationale behind the use of this experimental protocol was to resemble an acute (6 h) and 'chronic' (24 h) lithium treatment. As seen in Figure 3 , pretreatment with 1 mM lithium for 6 h (A) and 24 h (B) before LPS did not significantly alter LPS-induced secretion of NO. On the other hand, pretreatment with 10 mM lithium for 6 h (C) and 24 h (D) significantly reduced LPS-induced secretion of NO. Similarly, as seen in Figure 4 , pretreatment with 1 mM lithium for 6 h (A) and 24 h (B) did not reduce LPSinduced secretion of TNF-a. On the other hand, pretreatment with 10 mM lithium for 6 h (C) and 24 h (D) significantly reduced LPS-induced secretion of TNF-a. Moreover, as seen in Figure 5 , pretreatment with 1 mM lithium for 6 h (A) significantly reduced LPS-induced secretion of IL-1b. Likewise, pretreatment with 10 mM lithium for 6 h (C) and 24 h (D) also significantly reduced LPS-induced secretion of IL-1b. Contrastingly, 1 mM lithium did not alter IL-1b levels when the drug was given 24 h before LPS (B). Furthermore, similar results were obtained in regard to the effect of lithium on LPS (5000 ng/ml)-induced secretion of PGE 2 . In these experiments, we used ibuprofen (a non-selective COX inhibitor) as a positive control. As seen in Figure 6 , pretreatment with 1 mM lithium for 6 h (A) and 24 h (B) did not significantly alter LPS-induced secretion of PGE 2 . Alternatively, pretreatment with 10 mM lithium for 6 h (C) and 24 h (D) significantly reduced LPS-induced secretion of PGE 2 . In all PGE 2 experiments, ibuprofen totally abolished LPS-induced secretion of PGE 2 .
Taken together, these results generally indicate that, while a therapeutically relevant concentration of lithium (1 mM) did not reduce LPS-induced secretion of the tested inflammatory mediators, a higher concentration (10 mM) significantly reduced the levels of all of them (NO, TNF-a, IL-1b and PGE 2 ).
Effects of lithium on LPS-induced expression of iNOS and COX-2
These experiments were conducted in order to examine whether the effects of lithium on LPS-induced secretion of NO and PGE 2 are caused by the suppression of iNOS and COX-2 expression. Lithium was added to the culture medium at 6 h before treatment with LPS (5000 ng/ml), and LPS was added for another 18 h. As seen in Figure 7 , lithium alone did not alter iNOS expression and was similar to control. Pretreatment with lithium (1 or 10 mM) significantly reduced LPS-induced expression of iNOS. Moreover, the effects of lithium on COX-2 expression were similar to its effect on iNOS. As seen in Figure 8 , lithium alone did not significantly alter COX-2 expression and was similar to control. Pretreatment with lithium 10 mM (but not 1 mM) significantly reduced LPS-induced expression of COX-2. 
Discussion
The major finding of our study is that lithium reduced LPS-induced inflammation in rat primary glia cells. This confirms previous reports in which lithium reduced LPSinduced inflammation in mouse glia cells. 78, 79 Lithium reduced production of the pro-inflammatory mediators NO, TNF-a, IL-1b and PGE 2 after stimulation with bacterial endotoxin. Moreover, lithium attenuated LPS-induced expression of iNOS and COX-2, which generate NO and PGE 2 , respectively.
The accepted therapeutic level of lithium in bipolar patients is 0.6-1.2 mM. It is important to emphasize that, in the current study, the anti-inflammatory effects of lithium were obtained at a concentration of 10 mM, which is extra-therapeutic but widely used in lithium's pharmacology research. At a therapeutically-relevant concentration (1 mM), lithium did not significantly reduce LPS-induced inflammation. It is worth noting that other studies that reported a significant anti-inflammatory effect for lithium after LPS induction also used extra-therapeutic concentrations (10-20 mM) of the drug. [78] [79] [80] Moreover, the therapeutic efficacy of lithium is observed mainly when it is given as a prophylactic treatment against recurrent manic, or depressive, episodes. 1, 2 The acute clinical effect of lithium alone on mania or depression is low. Thus, if (brain) inflammation is indeed associated with clinical exacerbations, a therapeutic effect of lithium may necessitate much higher doses than those given for prophylactic treatment. This may explain why high doses of lithium are necessary in order to observe a potent anti-inflammatory effect.
Interestingly, Bosetti et al. have shown that chronic treatment with lithium, which led to a therapeuticallyrelevant plasma concentration (0.74 + 0.03 mM), significantly reduced COX-2 activity and PGE 2 levels in rat brain. 61 The discrepancy between the results of our study and those of the previous report 61 may stem from methodological differences. Importantly, Bosetti et al. did not examine the effects of lithium on LPS (or other inflammatory stimuli)-induced inflammation, but rather determined its effects on basal COX-2 activity and PGE 2 levels. 61 In addition, in their study, lithium was administered for a total duration of 6 wk. Therefore, although in our study lithium 1 mM did not cause a significant reduction in secretion of inflammatory mediators and expression of inflammatoryassociated enzymes (except for iNOS), a long-term exposure to lithium (as in bipolar patients) may still lead to significant anti-inflammatory effects. This may also be true as in our experimental protocol, LPS was used to induce an acute inflammatory response. The magnitude of a possible (chronic) inflammatory process in bipolar patients is not necessarily as high as the one induced by an acute LPS stimulation in vitro. A lower magnitude inflammatory response may be well 'contained' by chronic treatment with 1 mM lithium. In our study, lithium was administered at 6 h and 24 h before exposure to LPS. The rationale for using these two times was to mimic a short-term (acute) and a long-term (chronic) treatment protocols. We are aware that treatment with lithium for a total of 42 h is not a typical 'chronic' treatment protocol; however, we aimed to prolong, as much as possible, the exposure time to lithium in order to examine whether a time-dependent effect exists. Although the results indicate that there is no significant difference between the two treatment courses (pretreatment with lithium for 6 h versus 24 h), it cannot be ruled out that a long-term (4-6 wk) treatment protocol will lead to different results. On the other hand, it is possible that even a long-term treatment with lithium 1 mM will not lead to potent (significant) anti-inflammatory effects. We could not conduct a long-term treatment protocol because of a technical limitation-when we begin experiments with the primary glia cultures, cells are already 2-3 wk old (after extraction) and they remain viable for another 1-2 wk. This does not allow conduction of a long-term (4-6 wk) treatment protocol with lithium.
Nevertheless, the results of our study support the accumulating evidence indicating that lithium and other mood-stabilizing drugs 61-64,81-84 exert anti-inflammatory properties and that inflammation may contribute to the pathophysiological mechanisms underlying bipolar disorder. 49 The precise mechanism by which lithium inhibits inflammation is not known. Several pharmacological properties of lithium may account for its anti-inflammatory effect. For example, lithium inhibits the multi-functional enzyme glycogen synthase kinase-3 (GSK-3). 17, 85, 86 Inhibition of GSK-3 has been associated with attenuation of inflammatory responses in different experimental models. [78] [79] [80] [87] [88] [89] [90] Consistently, lithium inhibition of GSK-3 led to a significant reduction in the secretion of inflammatory mediators and expression of inflammatory enzymes. [78] [79] [80] 87 Relevant to the present study, Jope and co-workers have shown that lithium (20 mM) significantly reduced LPS-induced secretion of IL-6 in mouse primary astrocytes 78 and decreased the levels of IL-6, NO, iNOS and COX-2 in mouse microglia BV-2 cells. 79 Moreover, inhibition of GSK-3 by lithium was found to decrease the transcriptional activity of NFk-B, 80, 87 which may explain the antiinflammatory effect of lithium. Other pharmacological effects of lithium may also contribute to its antiinflammatory activity.
Cytokines such as IL-1b and TNF-a affect cognition, learning and memory. Furthermore, considerable data associated cytokines to CNS neurotransmission and behavior. For example, TNF-a has been reported to reduce serotonin availability in the synaptic cleft by increasing the activity of serotonin transporter. 91 Contrastingly, IL-1b was shown to stimulate the release of serotonin, norepinephrine and dopamine in rat hypothalamus. 92 These findings suggest that cytokines play a role in brain function and affect behavior. We examined the effects of lithium on LPS-induced secretion of IL-1b and TNF-a. Lithium 1 and 10 mM significantly reduced IL-1b levels. This result was consistent in multiple experiments, irrespective of the pretreatment time with lithium (6 h or 24 h). Therefore, the inhibitory effect of lithium on IL-1b secretion may exert a therapeutic effect. On the other hand, only at a concentration of 10 mM did lithium significantly reduce TNF-a levels; at a concentration of 1 mM, lithium significantly increased TNF-a levels. The mechanism underlying the difference in the effect of lithium on IL-1b and TNF-a is not understood. However, the increase in TNF-a levels under treatment with 1 mM lithium is consistent with previous reports in which therapeutic concentrations of lithium significantly increased plasma TNF-a levels in bipolar patients. 93, 94 Furthermore, the mood stabilizer valproate has been shown to reduce the release of TNF-a, interferon-g, NO and reactive oxygen species in primary rat neuron-glia cultures. 83 Another study showed that valproate reduces TNF-a and IL-6 production. 81 In our study, lithium 1 and 10 mM led to a significant reduction in LPS-induced iNOS expression. However, only lithium 10 mM significantly decreased LPS-induced secretion of NO. In this regard, it is worth noting that the effect of lithium 1 mM on expression of iNOS (and COX-2) was not consistent in all experiments that we conducted. In most of the experiments, lithium 1 mM did not reduce LPS-induced expression of iNOS and COX-2. However, in some experiments it did reduce the enzyme expression. This discrepancy in lithium's effect explains the relatively large standard errors seen in Figures 7 and 8 (iNOS and COX-2, respectively). We do not know the exact reason for this inconsistency, however, a different magnitude response-to-LPS may be a partial explanation. Namely, that the same LPS concentration led to a different extent expression of iNOS and COX-2 in various experiments.
In summary, the present study demonstrates that lithium (10 mM) reduced LPS-induced inflammation in primary rat glia cells. More research is needed to elucidate the exact association between brain inflammation and the pathogenesis of bipolar disorder and the mechanisms by which mood stabilizers inhibit inflammation.
